PASSCLAIM - Diet-related cardiovascular disease

European Journal of Nutrition

Volumn 42, Issue SUPPL. 1, 2003, Pages i6-i27

  Mensink, Ronald P ^a   Aro, Antti ^b   Hond, Elly Den ^c   German, J Bruce ^d,e   Griffin, Bruce A ^f   Ter Meer, Hans Ulrich ^g   Mutanen, Marja ^h   Pannemans, Daphne ⁱ   Stahl, Wilhelm ^j  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d NESTLÉ RESEARCH CENTER   (Switzerland)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF SURREY   (United Kingdom)

^g SANOFI   (France)

^h UNIVERSITY OF HELSINKI   (Finland)

ⁱ International Life Sciences Institute of Europe   (Belgium)

^j HEINRICH HEINE UNIVERSITY   (Germany)

more..

Author keywords

Blood pressure; Cholesterol; Claims cardiovascular disease; Diet; HDL cholesterol hemostasis; Homocysteine; Oxidation; Triacylglycerol

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ARTICLE; BLOOD ANALYSIS; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIET; DIET RESTRICTION; FEASIBILITY STUDY; FOOD ANALYSIS; FOOD PREFERENCE; HEMOSTASIS; HUMAN; LABORATORY TEST; LITERATURE; OXIDATIVE STRESS; RISK ASSESSMENT; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BLOOD; BLOOD PRESSURE; CHOLESTEROL INTAKE; CONSENSUS DEVELOPMENT; FOOD INDUSTRY; METABOLISM; NUTRITIONAL VALUE; REVIEW; RISK FACTOR;

ANIMALS; BIOLOGICAL MARKERS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL, DIETARY; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CONSENSUS DEVELOPMENT CONFERENCES; FOOD INDUSTRY; HEMOSTASIS; HOMOCYSTEINE; HUMANS; NUTRITIVE VALUE; RISK FACTORS; TRIGLYCERIDES;

EID: 3042513102     PISSN: 14366207     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00394-003-1102-2     Document Type: Article

References (172)

1. Anonymous (2001) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285:2486-2497
2. Knopp RH (1999) Drug treatment of lipid disorders. N Engl J Med 341:498-511
3. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333:1301-1307
4. Mensink RP, Katan MB (1992) Effect of dietary fatty acids on serum lipids and lipoproteins. A meta-analysis of 27 trials. Arterioscler Thromb 12:911-919
5. Cosio FG, Pesavento TE, Pelletier RP, Henry M, Ferguson RM, Kim S, Lemeshow S (2002) Patient survival after renal transplantation III: the effects of statins. Am J Kidney Dis 40:638-643
6. Parks EJ, Hellerstein MK (2000) Carbohydrate-induced hypertriacylglycerolemia: historical perspective and review of biological mechanisms. Am J Clin Nutr 71:412-433
7. Berneis KK, Krauss RM (2002) Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 43:1363-1379
8. Mann JI (2002) Diet and risk of coronary heart disease and type 2 diabetes. Lancet 360:783-789
9. Sacks FM (2002) The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 90:139-143
10. Keys A (1970) Coronary heart disease in seven countries. Circulation 41:I-186-I-198
11. Smith EB, Slater RS (1972) Relationship between low-density lipoprotein in aortic intima and serum-lipid levels. Lancet 1:463-469
12. Steinberg D, Witztum JL (1990) Lipoproteins and atherogenesis. Current concepts. JAMA 264:3047-3052
13. Stamler J, Wentworth D, Neaton JD (1986) Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 256:2823-2828
14. Anonymous (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389
15. Ballantyne CM, Herd JA, Dunn JK, Jones PH, Farmer JA, Gotto AM, Jr. (1997) Effects of lipid lowering therapy on progression of coronary and carotid artery disease. Curr Opin Lipidol 8:354-361
16. Castelli WP (1984) Epidemiology of coronary heart disease: the Framingham study. Am J Med 76:4-12
17. Fruchart JC, Packard CJ (1997) Is cholesterol the major lipoprotein risk factor in coronary heart disease? - A Franco-Scottish overview. Curr Med Res Opin 13:603-616
18. Griffin BA, Fielding BA (2001) Postprandial lipid handling. Curr Opin Clin Nutr Metab Care 4:93-98
19. O'Meara NM, Lewis GF, Cabana VG, Iverius PH, Getz GS, Polonsky KS (1992) Role of basal triglyceride and high density lipoprotein in determination of postprandial lipid and lipoprotein responses. J Clin Endocrinol Metab 75:465-471
20. Williams CM (1997) Cardiovascular risk factors in women. Proc Nutr Soc 56:383-391
21. Bainton D, Miller NE, Bolton CH, Yarnell JW, Sweetnam PM, Baker IA, Lewis B, Elwood PC (1992) Plasma triglyceride and high density lipoprotein cholesterol as predictors of ischaemic heart disease in British men. The Caerphilly and Speedwell Collaborative Heart Disease Studies. Br Heart J 68:60-66
22. Assmann G, Schulte H, von Eckardstein A, Huang Y (1996) High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis. 124 (Suppl): S11-S20
23. Cuchel M, Stott DJ, Gaw A, Vergani C, Packard CJ (2000) Atherogenic lipid profile in elderly patients with ischaemic cerebrovascular disease. Lancet 356:401-402
24. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V (1987) Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317:1237-1245
25. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J (1999) Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341:410-418
26. Ericsson CG, Nilsson J, Grip L, Svane B, Hamsten A (1997) Effect of bezafibrate treatment over five years on coronary plaques causing 20 % to 50 % diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT]). Am J Cardiol 80:1125-1129
27. Alaupovic P, Mack WJ, Knight-Gibson C, Hodis HN (1997) The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. Arterioscler Thromb Vasc Biol 17:715-722
28. Schaefer EJ, Lamon-Fava S, Ordovas JM, Cohn SD, Schaefer MM, Castelli WP, Wilson PW (1994) Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study. J Lipid Res 35:871-882
29. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH (1991) A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 325:373-381
30. Miller GJ, Miller NE (1975) Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet 1:16-19
31. Oram JF, Lawn RM (2001) ABCA1. The gatekeeper for eliminating excess tissue cholesterol. J Lipid Res 42:1173-1179
32. Chapman MJ (1980) Animal lipoproteins: chemistry, structure, and comparative aspects. J Lipid Res 21:789-853
33. Barter P (1993) High density lipoproteins and reverse cholesterol transport. Curr Ops Lipidol 4:210-217
34. Gofman J (1953) Index of coronary artery disease. Mod Med 21:119-140
35. Albrink MJ, Man EB (1959) Serum triglycerides in coronary artery disease. Arch Intern Med 103:4-8
36. Gaziano JM, Hennekens CH, O'Donnell CJ, Breslow JL, Buring JE (1997) Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation 96:2520-2525
37. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, Hennekens CH (1996) A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 276:882-888
38. Hokanson JE, Austin MA (1996) Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 3:213-219
39. Zilversmit DB (1979) Atherogenesis: a postprandial phenomenon. Circulation 60:473-485
40. Patsch JR, Miesenbock G, Hopferwieser T, Muhlberger V, Knapp E, Dunn JK, Gotto AM, Jr, Patsch W (1992) Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler Thromb 12:1336-1345
41. Griffin BA, Freeman DJ, Tait GW, Thomson J, Caslake MJ, Packard CJ, Shepherd J (1994) Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subtractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis 106:241-253
42. Lahdenpera S, Syvanne M, Kahri J, Taskinen MR (1996) Regulation of low-density lipoprotein particle size distribution in NIDDM and coronary disease: importance of serum triglycerides. Diabetologia 39:453-461
43. Brouns F, van der Vusse GJ (1998) Utilization of lipids during exercise in human subjects: metabolic and dietary constraints. Br J Nutr 79:117-128
44. nd edition). Butterworth-Heinemann Ltd, Oxford, pp 72-103
45. Sattar N, Petrie JR, Jaap AJ (1998) The atherogenic lipoprotein phenotype and vascular endothelial dysfunction. Atherosclerosis 138:229-235
46. Griffin BA (1995) Low-density lipoprotein heterogeneity. Baillieres Clin Endocrinol Metab 9:687-703
47. Austin MA (1991) Plasma triglyceride and coronary heart disease. Arterioscler Thromb 11:2-14
48. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM (1988) Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260:1917-1921
49. Hornstra G, Barth CA, Galli C, Mensink RP, Mutanen M, Riemersma RA, Roberfroid M, Salminen K, Vansant G, Verschuren PM (1998) Functional food science and the cardiovascular system. Br J Nutr 80 (Suppl 1):S113-S146
50. Brown AA, Hu FB (2001) Dietary modulation of endothelial function: implications for cardiovascular disease. Am J Clin Nutr 73:673-686
51. Hunt BJ, Jurd KM (1998) Endothelial cell activation. A central pathophysiological process. BMJ 316:1328-1329
52. Wiman B, Andersson T, Hallqvist J, Reuterwall C, Ahlbom A, deFaire U (2000) Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study. Arterioscler Thromb Vasc Biol 20:2019-2023
53. Cox DA, Vita JA, Treasure CB, Fish RD, Alexander RW, Ganz P, Selwyn AP (1989) Atherosclerosis impairs flow-mediated dilation of coronary arteries in humans. Circulation 80:458-465
54. Zeiher AM, Drexler H, Wollschlager H, Just H (1991) Endothelial dysfunction of the coronary microvasculature is associated with coronary blood flow regulation in patients with early atherosclerosis. Circulation 84:1984-1992
55. Hogikyan RV, Galecki AT, Pitt B, Halter JB, Greene DA, Supiano MA (1998) Specific impairment of endothelium-dependent vasodilation in subjects with type 2 diabetes independent of obesity. J Clin Endocrinol Metab 83:1946-1952
56. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J (1998) Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 351:88-92
57. Mutanen M, Freese R (1996) Polyunsaturated fatty acids and platelet aggregation. Curr Opin Lipidol 7:14-19
58. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, Haines AP, Stirling Y, Imeson JD, Thompson SG (1986) Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 2:533-537
59. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB (1987) Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 258: 1183-1186
60. Danesh J, Collins R, Peto R (2000) Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 102:1082-1085
61. Antithrombotic Trialists' Collaboration (2002) Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71-86
62. Cannon RO, III (2000) Cardiovascular benefit of cholesterol-lowering therapy: does improved endothelial vasodilator function matter? Circulation 102:820-822
63. Stec JJ, Silbershatz H, Tofler GH, Matheney TH, Sutherland P, Lipinska I, Massaro JM, Wilson PF, Muller JE, D'Agostino RB, Sr. (2000) Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Offspring Population. Circulation 102:1634-1638
64. Mutanen M, Freese R (2001) Fats, lipids and blood coagulation. Curr Opin Lipidol 12:25-29
65. Misikangas M, Freese R, Turpeinen AM, Mutanen M (2001) High linoleic acid, low vegetable, and high oleic acid, high vegetable diets affect platelet activation similarly in healthy women and men. J Nutr 131:1700-1705
66. Thorngren M, Gustafson A (1981) Effects of 11-week increases in dietary eicosapentaenoic acid on bleeding time, lipids, and platelet aggregation. Lancet 2:1190-1193
67. Freese R, Mutanen M (1997) Alpha-linolenic acid and marine long-chain n-3 fatty acids differ only slightly in their effects on hemostatic factors in healthy subjects. Am J Clin Nutr 66:591-598
68. Sies H (1997) Antioxidants in Disease Mechanisms and Therapy. Academic press, London
69. rd edn. Oxford University Press, Oxford
70. Witztum JL, Steinberg D (2001) The oxidative modification hypothesis of atherosclerosis: does it hold for humans? Trends Cardiovasc Med 11:93-102
71. Stahl W, Ale-Agha N, Polidori CM (2002) Non-antioxidant properties of carotenoids. Biol Chem 383:553-558
72. Azzi A, Breyer I, Feher M, Ricciarelli R, Stocker A, Zimmer S, Zingg J (2001) Nonantioxidant functions of alpha-to-copherol in smooth muscle cells. J Nutr 131:378S-381S
73. Traber MG (2001) Does vitamin E decrease heart attack risk? Summary and implications with respect to dietary recommendations. J Nutr 131:395S-397S
74. Biesalski HK, Böhles H, Esterbauer H, Fürst P, Gey F, Hundsdörfer G, Kasper H, Sies H, Weisburger J (1997) Antioxidant vitamins in prevention. Clin Nutr 16:151-155
75. Ursini F, Tubaro F, Rong J, Sevanian A (1999) Optimization of nutrition: polyphenols and vascular protection. Nutr Rev 57:241-249
76. Carr AC, Zhu BZ, Frei B (2000) Potential antiatherogenic mechanisms of ascorbate (vitamin C) and alpha-tocopherol (vitamin E). Circ Res 87:349-354
77. Eichholzer M, Luthy J, Gutzwiller F, Stahelin HB (2001) The role of folate, antioxidant vitamins and other constituents in fruit and vegetables in the prevention of cardiovascular disease: the epidemiological evidence. Int J Vitam Nutr Res 71:5-17
78. Pryor WA (1-1-2000) Vitamin E and heart disease: basic science to clinical intervention trials. Free Radic Biol Med 28:141-164
79. Duthie GG, Bellizzi MC (1999) Effects of antioxidants on vascular health. Br Med Bull 55:568-577
80. Halliwell B (1999) Establishing the significance and optimal intake of dietary antioxidants: the biomarker concept. Nutr Rev 57:104-113
81. de Zwart LL, Meerman JH, Commandeur JN, Vermeulen NP (1999) Biomarkers of free radical damage applications in experimental animals and in humans. Free Radic Biol Med 26:202-226
82. Moore K, Roberts LJ (1998) Measurement of lipid peroxidation. Free Radic Res 28:659-671
83. Diplock AT (2000) Introduction: markers of oxidative damage and antioxidant modulation. Free Radic Res 33 (Suppl):S21-S26
84. Lindsay DG, Astley SB (2002) European research on the functional effects of dietary antioxidants EUROFEDA. Mol Aspects Med 23:1-38
85. Halliwell B, Chirico S (1993) Lipid peroxidation: its mechanism, measurement, and significance. Am J Clin Nutr 57:715S-724S
86. Mol MJ, de Rijke YB, Demacker PN, Stalenhoef AF (1997) Plasma levels of lipid and cholesterol oxidation products and cytokines in diabetes mellitus and cigarette smoking: effects of vitamin E treatment. Atherosclerosis 129:169-176
87. Rao AV, Agarwal S (1998) Bioavailability and in vivo antioxidant properties of lycopene from tomato products and their possible role in the prevention of cancer. Nutr Cancer 31:199-203
88. Rust P, Eichler I, Renner S, Elmadfa I (2000) Long-term oral beta-carotene supplementation in patients with cystic fibrosis. Ann Nutr Metab 44:30-37
89. Young JF, Dragsted LO, Daneshvar B, Lauridsen ST, Hansen M, Sandstrom B (2000) The effect of grape-skin extract on oxidative status. Br J Nutr 84:505-513
90. Packer L (1999) Oxidants and Antioxidants. Methods in Enzymology, ed by L. Packer, volume 300
91. Aghdassi E, Allard JP (2000) Breath alkanes as a marker of oxidative stress in different clinical conditions. Free Radic Biol Med 28:880-886
92. Kohlmüller D, Kochen W (1993) Is n-pentane really an index of lipid peroxidation in humans and animals? A methodological reevaluation. Anal Biochem 210:268-276
93. Roberts LJ, Morrow JD (2002) Products of the isoprostane pathway: unique bioactive compounds and markers of lipid peroxidation. Cell Mol Life Sci 59:808-820
94. Dietrich M, Block G, Hudes M, Morrow JD, Norkus EP, Traber MG, Cross CE, Packer L (2002) Antioxidant supplementation decreases lipid peroxidation biomarker F(2)-isoprostanes in plasma of smokers. Cancer Epidemiol Biomarkers Prev 11:7-13
95. Freese R, Basu S, Hietanen E, Nair J, Nakachi K, Bartsch H, Mutanen M (1999) Green tea extract decreases plasma malondialdehyde concentration but does not affect other indicators of oxidative stress, nitric oxide production, or hemostatic factors during a high-linoleic acid diet in healthy females. Eur J Nutr 38:149-157
96. Hodgson JM, Croft KD, Mori TA, Burke V, Beilin LJ, Puddey IB (2002) Regular ingestion of tea does not inhibit in vivo lipid peroxidation in humans. J Nutr 132:55-58
97. Rice-Evans C, Leake D, Bruckdorfer KR, Diplock AT (1996) Practical approaches to low density lipoprotein oxidation: whys, wherefores and pitfalls. Free Radic Res 25:285-311
98. Cadenas E, Sies H (1998) The lag phase. Free Radic Res 28:601-609
99. Ziouzenkova O, Gieseg SP, Ramos P, Esterbauer H (1996) Factors affecting resistance of low density lipoproteins to oxidation. Lipids 31 (Suppl): S71-S76
100. Astley S, Langrish-Smith A, Southon S, Sampson M (1999) Vitamin E supplementation and oxidative damage to DNA and plasma LDL in type 1 diabetes. Diabetes Care 22:1626-1631
101. Chopra M, Fitzsimons PE, Strain JJ, Thurnham DI, Howard AN (2000) Nonalcoholic red wine extract and quercetin inhibit LDL oxidation without affecting plasma antioxidant vitamin and carotenoid concentrations. Clin Chem 46:1162-1170
102. Upritchard JE, Sutherland WH, Mann JI (2000) Effect of supplementation with tomato juice, vitamin E, and vitamin C on LDL oxidation and products of inflammatory activity in type 2 diabetes. Diabetes Care 23:733-738
103. Polidori MC, Stahl W, Eichler O, Niestroj I, Sies H (2001) Profiles of antioxidants in human plasma. Free Radic Biol Med 30:456-462
104. Rissanen TH, Voutilainen S, Nyyssonen K, Lakka TA, Sivenius J, Salonen R, Kaplan GA, Salonen JT (2001) Low serum lycopene concentration is associated with an excess incidence of acute coronary events and stroke: the Kuopio Ischaemic Heart Disease Risk Factor Study. Br J Nutr 85:749-754
105. Dwyer JH, Navab M, Dwyer KM, Hassan K, Sun P, Shircore A, Hama-Levy S, Hough G, Wang X, Drake T, Merz CN, Fogelman AM (2001) Oxygenated carotenoid lutein and progression of early atherosclerosis: the Los Angeles atherosclerosis study. Circulation 103:2922-2927
106. Asplund K (2002) Antioxidant vitamins in the prevention of cardiovascular disease: a systematic review. J Intern Med 251:372-392
107. Kris-Etherton PM, Keen CL (2002) Evidence that the antioxidant flavonoids in tea and cocoa are beneficial for cardiovascular health. Curr Opin Lipidol 13:41-49
108. Institute of Medicine FaNB (2000) Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium and Carotenoids. National Academy Press, Washington DC
109. Griffiths HR, Moller L, Bartosz G, Bast A, Bertoni-Freddari C, Collins A, Cooke M, Coolen S, Haenen G, Hoberg AM, Loft S, Lunec J, Olinski R, Parry J, Pompella A, Poulsen H, Verhagen H, Astley SB (2002) Biomarkers. Mol Aspects Med 23:101-208
110. Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:23-33
111. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, Albers JJ (2001) Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345:1583-1592
112. Fang JC, Kinlay S, Beltrame J, Hikiti H, Wainstein M, Behrendt D, Suh J, Frei B, Mudge GH, Selwyn AP, Ganz P (2002) Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomised trial. Lancet 359:1108-1113
113. Sawayama Y, Shimizu C, Maeda N, Tatsukawa M, Kinukawa N, Koyanagi S, Kashiwagi S, Hayashi J (2002) Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). J Am Coll Cardiol 39:610-616
114. Meagher E, Rader DJ (2001) Antioxidant therapy and atherosclerosis: animal and human studies. Trends Cardiovasc Med 11:162-165
115. Chisolm GM, Steinberg D (2000) The oxidative modification hypothesis of atherogenesis: an overview. Free Radic Biol Med 28:1815-1826
116. Dhalla NS, Temsah RM, Netticadan T (2000) Role of oxidative stress in cardiovascular diseases. J Hypertens 18:655-673
117. Pratico D (2001) Lipid peroxidation in mouse models of atherosclerosis. Trends Cardiovasc Med 11:112-116
118. Jang Y, Lee JH, Kim OY, Park HY, Lee SY (2001) Consumption of whole grain and legume powder reduces insulin demand, lipid peroxidation, and plasma homocysteine concentrations in patients with coronary artery disease: randomized controlled clinical trial. Arterioscler Thromb Vasc Biol 21:2065-2071
119. Liu S, Lee IM, Ajani U, Cole SR, Buring JE, Manson JE (2001) Intake of vegetables rich in carotenoids and risk of coronary heart disease in men: The Physicians' Health Study. Int J Epidemiol 30:130-135
120. John JH, Ziebland S, Yudkin P, Roe LS, Neil HA (2002) Effects of fruit and vegetable consumption on plasma antioxidant concentrations and blood pressure: a randomised controlled trial. Lancet 359:1969-1974
121. Krauss RM, Eckel RH, Howard B, Appel LJ, Daniels SR, Deckelbaum RJ, Erdman JW, Jr, Kris-Etherton P, Goldberg IJ, Kotchen TA, Lichtenstein AH, Mitch WE, Mullis R, Robinson K, Wylie-Rosett J, St Jeor S, Suttie J, Tribble DL, Bazzarre TL (2000) AHA Dietary Guidelines: revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Stroke 31:2751-2766
122. Trichopoulou A, Vasilopoulou E (2000) Mediterranean diet and longevity. Br J Nutr 84 (Suppl 2): S205-S209
123. Tavani A, La Vecchia C (1999) Beta-carotene and risk of coronary heart disease. A review of observational and intervention studies. Biomed Pharmacother 53:409-416
124. Stocker R (1999) Dietary and pharmacological antioxidants in atherosclerosis. Curr Opin Lipidol 10:589-597
125. van't Veer PV, Kok FJ (2000) Human studies to substantiate health effects of antioxidants. What is needed? Free Radic Res 33 (Suppl):S109-S115
126. Czernichow S, Hercberg S (2001) Interventional studies concerning the role of antioxidant vitamins in cardiovascular diseases: a review. J Nutr Health Aging 5:188-195
127. Evans P, Halliwell B (2001) Micronutrients: oxidant/antioxidant status. Br J Nutr 85 (Suppl 2):S67-S74
128. Eikelboom JW, Lonn E, Genest J, Jr, Hankey G, Yusuf S (1999) Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 131:363-375
129. Wald DS, Bishop L, Wald NJ, Law M, Hennessy E, Weir D, McPartlin J, Scott J (2001) Randomized trial of folic acid supplementation and serum homocysteine levels. Arch Intern Med 161:695-700
130. Brouwer IA, van Dusseldorp M, West CE, Meyboom S, Thomas CM, Duran M, het Hof KH, Eskes TK, Hautvast JG, Steegers-Theunissen RP (1999) Dietary folate from vegetables and citrus fruit decreases plasma homocysteine concentrations in humans in a dietary controlled trial. J Nutr 129:1135-1139
131. Brouwer IA, Verhoef P, Urgert R (2000) Betaine supplementation and plasma homocysteine in healthy volunteers. Arch Intern Med 160:2546-2547
132. Schwab U, Torronen A, Toppinen L, Alfthan G, Saarinen M, Aro A, Uusitupa M (2002) Betaine supplementation decreases plasma homocysteine concentrations but does not affect body weight, body composition, or resting energy expenditure in human subjects. Am J Clin Nutr 76:961-967
133. Meleady R, Graham I (1999) Plasma homocysteine as a cardiovascular risk factor: causal, consequential, or of no consequence? Nutr Rev 57:299-305
134. Homocysteine studies collaboration (2002) Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288:2015-2022
135. Knekt P, Reunanen A, Alfthan G, Heliovaara M, Rissanen H, Marniemi J, Aromaa A (2001) Hyperhomocystinemia: a risk factor or a consequence of coronary heart disease? Arch Intern Med 161:1589-1594
136. Nurk E, Tell GS, Vollset SE, Nygard O, Refsum H, Ueland PM (2002) Plasma total homocysteine and hospitalizations for cardiovascular disease: the Hordaland Homocysteine Study. Arch Intern Med 162:1374-1381
137. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE (1997) Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 337:230-236
138. Bunout D, Petermann M, Hirsch S, de la MP, Suazo M, Barrera G, Kauffman R (2000) Low serum folate but normal homocysteine levels in patients with atherosclerotic vascular disease and matched healthy controls. Nutrition 16:434-438
139. Silberberg JS, Crooks RL, Wlodarczyk JH, Fryer JL (2001) Association between plasma folate and coronary disease independent of homocysteine. Am J Cardiol 87:1003-1004
140. Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, Andria G, Boers GH, Bromberg IL, Cerone R (1985) The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet 37:1-31
141. McCully KS, Wilson RB (1975) Homocysteine theory of arteriosclerosis. Atherosclerosis 22:215-227
142. Lentz SR, Piegors DJ, Malinow MR, Heistad DD (2001) Supplementation of atherogenic diet with B vitamins does not prevent atherosclerosis or vascular dysfunction in monkeys. Circulation 103:1006-1011
143. Schnyder G, Roffi M, Pin R, Flammer Y, Lange H, Eberli FR, Meier B, Turi ZG, Hess OM (2001) Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 345:1593-1600
144. Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM (2002) Effect of homocysteine-lowering therapy with folic acid, vitamin B(12), and vitamin B(6) on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial. JAMA 288:973-979
145. Brattstrom L, Wilcken DE, Ohrvik J, Brudin L (1998) Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation 98:2520-2526
146. Jee SH, Beaty TH, Suh I, Yoon Y, Appel LJ (2000) The methylenetetrahydrofolate reductase gene is associated with increased cardiovascular risk in Japan, but not in other populations. Atherosclerosis 153:161-168
147. Brattström L, Wilcken DEL (2000) Homocysteine and cardiovascular risk: cause or effect? Am J Clin Nutr 72:314-323
148. Christen WG, Ajani UA, Glynn RJ, Hennekens CH (2000) Blood levels of homocysteine and increased risks of cardiovascular disease: causal or casual? Arch Intern Med 160:422-434
149. Doshi SN, McDowell IF, Moat SJ, Payne N, Durrant HJ, Lewis MJ, Goodfellow J (2002) Folic acid improves endothelial function in coronary artery disease via mechanisms largely independent of homocysteine lowering. Circulation 105:22-26
150. The Joint National Committee on Prevention Detection Evaluation and Treatment of High Blood Pressure (1997) The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 157:2413-2446
151. Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, Labarthe D (1995) Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 25:305-313
152. Staessen J, Amery A, Fagard R (1990) Isolated systolic hypertension in the elderly. J Hypertens 8:393-405
153. Kannel WB (2000) Fiftyyears of Framingham Study contributions to understanding hypertension. J Hum Hypertens 14:83-90
154. Birkenhager WH, Forette F, Seux ML, Wang JG, Staessen JA (2001) Blood pressure, cognitive functions, and prevention of dementias in older patients with hypertension. Arch Intern Med 161:152-156
155. Forette F, Seux ML, Staessen JA, Thijs L, Birkenhager WH, Babarskiene MR, Babeanu S, Bossini A, Gil-Extremera B, Girerd X, Laks T, Lilov E, Moisseyev V, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Fagard R (1998) Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 352:1347-1351
156. Guidelines Subcommittee (1999) 1999 World Health Organization- International Society of Hypertension guidelines for the management of hypertension. J Hypertens 17:151-183
157. Petrie JC, O'Brien ET, Littler WA, de Swiet M (1986) Recommendations on blood pressure measurement by a working party of the British Hypertension Society. Brit Med J 293:611-615
158. O'Brien E, Waeber B, Parati G, Staessen J, Myers MG, on behalf of the European Society of Hypertension (2001) Blood pressure measuring devices: recommendations of the European Society of Hypertension. Brit Med J 322:531-536
159. Staessen JA, Thijs L, Fagard R, O'Brien ET, Clement D, de Leeuw PW, Mancia G, Nachev C, Palatini P, Parati G, Tuomilehto J, Webster J, for the Systolic Hypertension in Europe Trial Investigators (1999) Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. JAMA 282:539-546
160. Kannel WB, Gordon T, Schwartz MJ (1971) Systolic versus diastolic blood pressure and risk of coronary heart disease. Am J Cardiol 27:335-346
161. Staessen JA, Gasowksi J, Wang JG, Thijs L, Den Hond E, Boissel J, Coope J, Ekbom T, Gueyffier F, Liu L, Kerlikowske K, Pocock S, Fagard RH (2000) Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 355:865-872
162. Franklin SS, Larson MG, Khan SA, Wong ND, Leip EP, Kannel WB, Levy D (2001) Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 103:1245-1249
163. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH (1990) Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 355:827-838
164. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J (1990) Blood pressure, stroke and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 335:765-774
165. Stokes J, Kannel WB, Wolf PA, D'Agostino RB, Cupples LA (1989) Blood pressure as a risk factor for cardiovascular disease. The Framingham Study - 30 years of follow-up. Hypertension 13 (Suppl I):113-118
166. Kaplan NM (2001) Treatment of coexisting diabetes and hypertension. Curr Cardiol Rep 6:498-503
167. Cruickshank JM, Thorp JM, Zacharias EJ (1987) Benefits and potential harm of lowering high blood pressure. Lancet 1(8533):581-584
168. Staessen J, Bulpitt C, Clement D, De Leeuw P, Fagard R, Fletcher A, Forette F, Leonetti G, Nissinen A, O'Malley KO, Tuomilehto J, Webster J, Williams BO (1989) Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. Brit Med J 298:1552-1556
169. Port S, Demer L, Jennrich R, Walter D, Garfinkel A (2000) Systolic blood pressure and mortality. Lancet 355:175-180
170. Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D (2001) Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet 358:1682-1686
171. Strauer BE, Motz W, Schwartzkopff B, Vester E, Leschke M, Scheler S (1994) The heart in hypertension. In: Swales JE (ed) Textbook of Hypertension. Blackwell Scientific Publications, Oxford, pp 712-731
172. Timberlake DS, O'Connor DT, Parmer RJ (2001) Molecular genetics of essential hypertension: recent results and emerging strategies. Curr Opin Nephrol Hypertens 10:71-79